The AAVLP (adeno-associated virus-like particles) programme is an innovative technology platform for the generation of new prophylactic and therapeutic vaccines. For this purpose, non-infectious virus-like particles derived from adeno-associated viruses (AAV) are used as epitope carriers. Epitopes delivered to the immune system in this way result in the production of specific antibodies. These antibodies in turn recognise the relevant epitope, e.g. on pathogens or mutant cancer cells, and consequently fight and/or protect against the relevant disease. Research into the use of the AAVLP technology to treat infectious diseases and cancer is being conducted by pursuing two different approaches. One is the direct integration of known epitopes. The second approach is based on the use of AAV libraries. Rather than defined epitopes, AAV libraries contain random sequences. Appropriate screening strategies enable the targeted selection of novel vaccine candidates from these libraries. The key benefit of this technology is the possibility of directly transferring the mode of action of existing therapeutically effective antibodies into an active vaccine.
The final results of the preclinical trial conducted in cooperation with Pennsylvania State University to demonstrate long-term protection against infection and cross-reactivity to various types of HPV are available. The data is positive and is expected to be published as part of a scientific publication as soon as possible.